NO991048D0 - Indazolderivater og deres anvendelse som inhibitorer av fosfodiesterase (PDE) type IV og fremstillingen av tumornekrosefaktor (TNF) - Google Patents

Indazolderivater og deres anvendelse som inhibitorer av fosfodiesterase (PDE) type IV og fremstillingen av tumornekrosefaktor (TNF)

Info

Publication number
NO991048D0
NO991048D0 NO991048A NO991048A NO991048D0 NO 991048 D0 NO991048 D0 NO 991048D0 NO 991048 A NO991048 A NO 991048A NO 991048 A NO991048 A NO 991048A NO 991048 D0 NO991048 D0 NO 991048D0
Authority
NO
Norway
Prior art keywords
pde
phosphodiesterase
tnf
inhibitors
preparation
Prior art date
Application number
NO991048A
Other languages
English (en)
Other versions
NO991048L (no
Inventor
Anthony Marfat
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO991048D0 publication Critical patent/NO991048D0/no
Publication of NO991048L publication Critical patent/NO991048L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO991048A 1996-09-04 1999-03-03 Indazolderivater og deres anvendelse som inhibitorer av fosfodiesterase (PDE) type IV og fremstillingen av tumornekrosefaktor (TNF) NO991048L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2544696P 1996-09-04 1996-09-04
PCT/IB1997/001023 WO1998009961A1 (en) 1996-09-04 1997-08-25 Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)

Publications (2)

Publication Number Publication Date
NO991048D0 true NO991048D0 (no) 1999-03-03
NO991048L NO991048L (no) 1999-05-03

Family

ID=21826124

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991048A NO991048L (no) 1996-09-04 1999-03-03 Indazolderivater og deres anvendelse som inhibitorer av fosfodiesterase (PDE) type IV og fremstillingen av tumornekrosefaktor (TNF)

Country Status (35)

Country Link
US (1) US6262040B1 (no)
EP (1) EP0931075A1 (no)
JP (2) JP3554337B2 (no)
KR (1) KR100338610B1 (no)
CN (1) CN1234031A (no)
AP (1) AP795A (no)
AR (1) AR008162A1 (no)
AU (1) AU724549B2 (no)
BG (1) BG64447B1 (no)
BR (1) BR9712005A (no)
CA (1) CA2264798A1 (no)
CO (1) CO4600636A1 (no)
DZ (1) DZ2303A1 (no)
EA (1) EA002113B1 (no)
GT (1) GT199700102A (no)
HN (1) HN1997000126A (no)
HR (1) HRP970478B1 (no)
HU (1) HUP9903248A3 (no)
ID (1) ID18157A (no)
IL (1) IL128642A0 (no)
IS (1) IS4979A (no)
MA (1) MA26439A1 (no)
NO (1) NO991048L (no)
NZ (1) NZ334213A (no)
OA (1) OA10985A (no)
PA (1) PA8437301A1 (no)
PE (1) PE107998A1 (no)
PL (1) PL332187A1 (no)
SK (1) SK27299A3 (no)
TN (1) TNSN97148A1 (no)
TR (1) TR199900481T2 (no)
TW (1) TW402595B (no)
WO (1) WO1998009961A1 (no)
YU (1) YU11299A (no)
ZA (1) ZA977903B (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
CA2309175A1 (en) * 1997-11-04 1999-05-14 Pfizer Products Inc. Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
IL135900A0 (en) * 1997-11-04 2001-05-20 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeuticaly active compounds
JP2000198734A (ja) * 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
US6191300B1 (en) 1999-04-16 2001-02-20 Eastman Chemical Company Process for the preparation of cyclopropylacetonitrile
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
SI1212089T1 (sl) 1999-08-21 2006-08-31 Altana Pharma Ag Sinergisticna kombinacija roflumilasta in salmeterola
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
CA2395196C (en) * 1999-12-23 2006-02-21 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
WO2001079198A1 (en) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinase
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7153871B2 (en) 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US20040146561A1 (en) * 2001-05-23 2004-07-29 Naoki Sakurai Compositions for promoting healing of bone fracture
EP1389467B1 (en) * 2001-05-23 2013-07-03 Mitsubishi Tanabe Pharma Corporation Therapeutic composition for the regenerative treatment of cartilage diseases
TWI221838B (en) 2001-08-09 2004-10-11 Tanabe Seiyaku Co Pyrazinoisoquinoline compound or naphthalene compound
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
AU2003262187A1 (en) * 2002-04-12 2003-10-27 Celgene Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CN1668733A (zh) * 2002-05-30 2005-09-14 细胞基因公司 利用jnk或mkk抑制剂调节细胞分化并治疗骨髓增生异常和脊髓发育不良综合症的方法
CN101423497A (zh) * 2002-07-19 2009-05-06 记忆药物公司 作为磷酸二酯酶4抑制剂的6-氨基-1h-吲唑和4-氨基苯并呋喃化合物
AU2003256616B2 (en) 2002-07-19 2009-08-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
WO2004046113A2 (en) * 2002-11-19 2004-06-03 Memory Pharmaceuticals Corporation Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06002608A (es) 2002-12-20 2007-01-23 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
JP2005089457A (ja) 2003-09-03 2005-04-07 Yung Shin Pharmaceutical Industry Co Ltd 骨成長を促進するまたは骨吸収を阻害するための薬剤組成物
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
KR20060114022A (ko) 2004-02-27 2006-11-03 에프. 호프만-라 로슈 아게 인다졸 유도체 및 그들을 함유하는 약학 조성물
MXPA06009462A (es) 2004-02-27 2007-03-15 Hoffmann La Roche Derivados pirazolo heteroaril fusionados.
CA2557575A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
CA2564199A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
EP1756090A1 (en) 2004-05-14 2007-02-28 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
EP1751142A1 (en) 2004-05-14 2007-02-14 Pfizer Products Incorporated Pyrimidines derivatives for the treatment of abnormal cell growth
CA2573369A1 (en) * 2004-07-12 2006-02-16 Merck & Co., Inc. Inhibitors of histone deacetylase
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
TW200621237A (en) 2004-11-01 2006-07-01 Wyeth Corp [(1-h-indazol-3-yl)methyl]phenols and (hydroxyphenyl)(1h-indazol-3-yl)methanones
EP1891060A2 (en) * 2005-05-30 2008-02-27 Ranbaxy Laboratories Limited 3-indazolyl-isoxazoline derivatives as inhibitors of phosphodiesterase type-iv
BRPI0615442A2 (pt) 2005-08-25 2011-05-17 Hoffmann La Roche inibidores de p38 map cinase e métodos para uso dos mesmos
US7781460B2 (en) 2005-09-05 2010-08-24 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-IV
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
DK1981851T3 (da) 2006-01-31 2012-03-19 Array Biopharma Inc Kinaseinhibitorer og fremgangsmåder til anvendelse deraf
WO2008026687A1 (fr) 2006-09-01 2008-03-06 Kyorin Pharmaceutical Co., Ltd. Dérivé de pyrazolopyridine carboxamide et inhibiteur de phosphodiestérase (pde) comprenant le dérivé
CN101616587A (zh) * 2006-12-05 2009-12-30 孙仲铭 吲唑化合物
AU2008224541B2 (en) 2007-03-14 2013-08-22 Sun Pharmaceutical Industries Limited Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
WO2010003084A2 (en) * 2008-07-02 2010-01-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
JP2012521429A (ja) * 2009-03-23 2012-09-13 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛治療用のｐ２ｘ３受容体アンタゴニスト
ES2545811T3 (es) 2010-04-22 2015-09-16 Janssen Pharmaceutica Nv Compuestos de indazol útiles como inhibidores de quetohexoquinasa
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2015166370A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
RU2019117556A (ru) * 2016-11-18 2020-12-18 Мерк Шарп И Доум Корп. Индазольные производные, пригодные в качестве ингибиторов диацилглицерид o-ацилтрансферазы 2
JP2022540200A (ja) 2019-07-11 2022-09-14 エスケイプ・バイオ・インコーポレイテッド Ｌｒｒｋ２阻害剤としてのインダゾールおよびアザインダゾール
CN112694474B (zh) * 2019-10-23 2022-03-18 四川大学 吲唑类衍生物及其制备方法和用途
US20240279828A1 (en) * 2021-05-31 2024-08-22 Genscript Usa Inc. Electrografted films for dna synthesis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE531433A (no) 1953-06-17
US4665397A (en) 1983-11-01 1987-05-12 Universal Photonics, Inc. Apparatus and method for a universal electronic locking system
GB8524157D0 (en) * 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
JPH061350B2 (ja) * 1985-07-26 1994-01-05 コニカ株式会社 ハロゲン化銀写真感光材料
JPS6250751A (ja) * 1985-08-29 1987-03-05 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
GB8609175D0 (en) * 1986-04-15 1986-05-21 Ici America Inc Heterocyclic carboxamides
AU626980B2 (en) 1989-02-02 1992-08-13 Astellas Pharma Inc. Tetrahydrobenzimidazole derivatives
DK0527736T3 (da) 1990-05-18 1997-10-20 Hoechst Ag Isoxazol-4-carboxylsyreamider og hydroxyalkyliden-cyanoacetamider, lægemidler indeholdende disse forbindelser og anvendelsen af disse lægemidler.
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
CA2166721C (en) * 1993-07-06 1999-07-27 Allen Jacob Duplantier Bicyclic tetrahydro pyrazolopyridines
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
AU692839B2 (en) 1994-02-17 1998-06-18 American Home Products Corporation Substituted biphenyl derivatives as phosphodiesterase inhibitors
WO1995027692A1 (en) 1994-04-08 1995-10-19 Smithkline Beecham Corporation Subtituted biphenyl tnf inhibitors
JPH08143525A (ja) * 1994-11-21 1996-06-04 Banyu Pharmaceut Co Ltd ヒドロキシ安息香酸アミド誘導体を有効成分とする骨疾患の予防・治療剤
ATE244713T1 (de) * 1996-06-25 2003-07-15 Pfizer Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) typs 4 und des tumor-necrosin-factors (tnf)
ATE211740T1 (de) * 1996-06-27 2002-01-15 Pfizer Substituierte indazolderivate

Also Published As

Publication number Publication date
CA2264798A1 (en) 1998-03-12
MA26439A1 (fr) 2004-12-20
NO991048L (no) 1999-05-03
ZA977903B (en) 1999-03-03
WO1998009961A1 (en) 1998-03-12
BR9712005A (pt) 1999-08-24
ID18157A (id) 1998-03-05
KR100338610B1 (ko) 2002-05-27
EP0931075A1 (en) 1999-07-28
GT199700102A (es) 1999-02-25
PL332187A1 (en) 1999-08-30
JP2000502724A (ja) 2000-03-07
TW402595B (en) 2000-08-21
EA199900183A1 (ru) 1999-08-26
AU3781397A (en) 1998-03-26
PA8437301A1 (es) 1999-12-27
HUP9903248A2 (hu) 2000-04-28
HN1997000126A (es) 1997-12-26
AP795A (en) 1999-12-28
IL128642A0 (en) 2000-01-31
IS4979A (is) 1999-02-16
CN1234031A (zh) 1999-11-03
JP2004217668A (ja) 2004-08-05
HRP970478B1 (en) 2002-10-31
BG103195A (en) 1999-09-30
KR20000068421A (ko) 2000-11-25
DZ2303A1 (fr) 2002-12-28
NZ334213A (en) 2000-08-25
BG64447B1 (en) 2005-02-28
AP9701080A0 (en) 1997-10-31
YU11299A (sh) 2001-07-10
HRP970478A2 (en) 1998-08-31
JP3554337B2 (ja) 2004-08-18
EA002113B1 (ru) 2001-12-24
AR008162A1 (es) 1999-12-09
US6262040B1 (en) 2001-07-17
SK27299A3 (en) 2000-10-09
AU724549B2 (en) 2000-09-28
HUP9903248A3 (en) 2000-07-28
PE107998A1 (es) 1999-01-30
TNSN97148A1 (fr) 2005-03-15
OA10985A (en) 2001-11-01
TR199900481T2 (xx) 1999-06-21
CO4600636A1 (es) 1998-05-08

Similar Documents

Publication Publication Date Title
NO991048D0 (no) Indazolderivater og deres anvendelse som inhibitorer av fosfodiesterase (PDE) type IV og fremstillingen av tumornekrosefaktor (TNF)
NO986103L (no) Substituerte indazol-derivater og deres anvendelse som fosfodiesterase (PDE)type IV - og tumornekrose-faktor (TNF)inhibitorer
NO985095D0 (no) Substituerte indazolderivater og deres anvendelse som inhibitorer fosfodiesterase (PDE) type IV og produksjon av tumornekrosefaktor (TNF)
EE200100717A (et) Indasooliühendid ja farmatseutilised kompositsioonid proteiini kinaaside inhibeerimiseks ja meetodid nende kasutamiseks
HUP0004512A3 (en) 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
DK1000039T3 (da) Substituerede quinazolinderivater og anvendelse deraf som tyrosinkinaseinhibitorer
DK1076657T3 (da) Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
NO20001102L (no) 2,3-diaryl-pyrazolo[1,5-B]pyridazinderivater, deres fremstilling og anvendelse som cyklo-oksygenase 2 (COX-2) inhibitorer
NO941679D0 (no) Gallesyrederivater, fremgangsmåte for fremstilling og deres anvendelse
AU2002226911A1 (en) Indol derivative and their use as inhibitors of p38 kinase
AU3885900A (en) Inhibitors of the egf-receptor tyrosine kinase and their use
HUP9902026A3 (en) Use of bicyclic 4-aralkylaminopyrimidine derivatives for producing pharmaceutical compositions having tyrosine kinase inhibitor effect, novel bicicyclic 4-aralkylaminopirimidine derivatives and pharmaceutical compositions containing them
DK1353912T3 (da) 2-Arylimino-2,3-dihydrothiazolderivater, fremgangsmåderne til deres fremstilling og deres terapeutiske anvendelse
DK0983249T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af substituerede indazolderivater
NO934227D0 (no) Pyrrolderivater, fremgangsm}te for deres fremstilling og terapeutiske anvendelse
AU2876000A (en) Tyrosine kinase inhibitors and methods of using the same